Option chain shows key data for Exicure's stock options at various strike prices and expiration dates. Traders use this information to analyze potential trades and assess market sentiment for Exicure.

Exicure (NASDAQ:XCUR) Stock, Option Chain

Exicure

Exicure Inc is an early-stage biotechnology company focused on developing nucleic acid therapies targeting ribonucleic acid against validated targets. It operates in a single segment which is Biotechnology.

Palantir, Salesforce, Okta, Meta, And Tesla: Why These 5 Stocks Are On Investors' Radars Today

BOXL

BWNB

COGT

DATS

GDTC

GETY

GORO

HCWC

KUKE

Infrared Cameras Holdings, Inc. - Common Stock

MSAI

NARI

RIME

SBEV

SLRN

SYRA

XCUR

XTIA

Why Inari Medical Shares Are Trading Higher By 21%; Here Are 20 Stocks Moving Premarket

marvell technology shutter

News

Pre-Market Outlook

Markets

Movers

Trading Ideas

BSLK

CNEY

CRGY

CTNT

ENSC

ESGL

GSX Techedu Inc. American Depositary Shares

GOTU

HRTX

HTOO

LUNR

MRVL

ORIS

PSTG

SOAR

TANH

VIRX

Why Marvell Technology Shares Are Trading Higher By Around 13%; Here Are 20 Stocks Moving Premarket

Netflix, TSMC, American Express, Moderna, And Tesla: Why These 5 Stocks Are On Investors' Radars Today

AKTS

ALLT

APTO

ARQQ

CDXC

DBGI

ELAB

KULR

LION

NIVF

Nuveen California Dividend Advantage Municipal Fund 2

QMCO

QUBT

RGTI

UXIN

XTKG

Why Uxin Shares Are Trading Higher; Here Are 20 Stocks Moving Premarket

Exicure Inc

Curate

Press Releases

Exicure, Inc. Enters into Purchase Agreements for $1.3 Million and $8.7 Million Equity Financing and Reports Third Quarter 2024 Financial Results

Exicure, Inc. Announces Shareholders Approve the $8.7 Million Equity Financing and Reports Executive Management and Board Changes

Exicure, Inc. Partners with GPCR Therapeutics to Fuel New Growth in Biotech

Exicure, Inc. Announces Purchase Agreement with GPCR Therapeutics Inc.

Exicure, Inc. (Nasdaq: XCUR) Announces Issuance of New Patent in Australia

Exicure, Inc. Reports Full Year 2024 Financial Results

Exicure, Inc. (Nasdaq: XCUR) Announces Their Next Step in Planning for a New Clinical Trial in Acute Myeloid Leukemia (AML)

Exicure, Inc. (Nasdaq: XCUR) Nears Completion of Phase 2 Study of GPC-100 in Multiple Myeloma

Exicure Completes Patient Enrollment in Phase 2 Study of GPC-100 for Stem Cell Mobilization in Multiple Myeloma Patients Undergoing Autologous Transplant

Exicure, Inc. Received Nasdaq Delinquency Notice on Late Filing of its Form 10-Q

ABVC BioPharma

Acrivon Therapeutics, Inc. - Common Stock

Acrivon Therapeutics

Akari Therapeutics Plc - American Depositary Shares

Akari Therapeutics

Artiva Biotherapeutics, Inc. - Common Stock

Artiva Biotherapeutics

Burning Rock Biotech Limited - American Depositary Shares

Burning Rock Biotech

Barinthus Biotherapeutics plc - American Depositary Shares

Barinthus Biotherapeutics

CAMP4 Therapeutics Corporation - Common Stock

Camp4 Therapeutics

Clene

Estrella Immunopharma, Inc. - Common Stock

Estrella Immunopharma

MiNK Therapeutics

Kala Bio

Karyopharm Therapeutics Inc. - Common Stock

Karyopharm Therapeutics

Kazia Therapeutics Limited - American Depositary Shares

Kazia Therapeutics

Lantern Pharma

Mersana Therapeutics, Inc. - Common Stock

Mersana Therapeutics

Mural Oncology

NuCana

OnKure Therapeutics, Inc. - Class A Common Stock

OnKure Therapeutics

PepGen

Pluri

Radiopharm Theranostics Limited - American Depositary Shares

Radiopharm Theranostics

Rein Therapeutics

Shuttle Pharmaceuticals Holdings, Inc. - common stock

Shuttle Pharmaceuticals

vTv Therapeutics Inc. - Class A Common Stock

vTv Therapeutics

Xilio Therapeutics

Chardan Capital

Comments

Exicure

Exicure (XCUR) Options

No option chain data available. Please try again later

Connect With Us

About Benzinga

Market Resources

Trading Tools & Education

Ring the Bell